| Background:Angina pectoris is a common disease of the cardiovascular system disease, studies have shown that platelet activation plays an important role in the development and progression of coronary heart disease. Of platelet activation, platelet surface glycoprotein expression level still a significant change detection activated platelet surface glycoprotein expression level of understanding of platelet activation. Currently, antiplatelet therapy is an important part of the secondary prevention of coronary heart disease. But antiplatelet Western medicine, though the role of fast, but the role of a single target, but easy to produce drug resistance and adverse reactions. The studies have shown that some of the Chinese medicine or the effective parts of traditional Chinese medicines ingredients has a the the role of of inhibiting platelet activation function, to can be prevention and treatment of the coronary heart disease angina pectoris.Objective:1. The use of flow cytometry accurate determination of unstable angina patients with platelet surface glycoprotein expression levels, to reveal coronary heart disease in patients with angina pectoris platelet activation exists.2. The use of flow cytometry accurate determination of unstable angina patients with blood stasis platelet surface glycoprotein expression levels, to reveal the functional relevance of blood stasis and platelet activation.3. Evaluation of sodium tanshinone II A injection in the treatment of coronary heart disease with unstable angina clinical efficacy in patients with blood stasis, to prove that the blood circulation medication unstable angina patients with blood stasis.4. Observed Tanshinone II A Sulfonate Injection on Unstable Angina patients with blood stasis platelet activation, from platelet activating molecular level reveals the purpose of traditional Chinese medicine by inhibiting platelet activation function, to the treatment of angina pectoris.Methods:1. Select coronary heart disease with unstable angina102patients,20cases of healthy people, the use of flow cytometry to determine and compare the two sets of platelet membrane surface glycoprotein protein CD63, CD42b, PAC-1expression levels.2. Select coronary heart disease with unstable angina82patients with blood stasis, unstable angina20non-blood stasis syndrome,20cases of healthy people, the use of flow cytometry to determine and compare the three groups of platelet surface glycoprotein CD63, CD42b, PAC-1expression levels.3. Select coronary heart disease with unstable angina blood stasis syndrome,82cases were randomly divided into two groups, the control group were treated with western medicine, the treatment group in western medicine based on the addition of sodium tanshinone Ⅱ A injection treatment for14days before and after the the the treatment of of the, the use of measured by flow cytometry the surface of the platelet membrane in patients with sugar protein CD63, CD42b, PAC-1the expression level of, and evaluate the the the clinical efficacy of of the the two groups.4. All test data into the computer, the application of statistical software SPSS17.0statistical analysis. Measurement data were presented as mean±standard deviation (x±s), count data using the frequency. Measurement data between groups using independent sample t-test, the group before and after treatment using paired t test, count χ2test was used to compare data between groups. P<0.05was statistically significant difference.Results:1. Coronary heart disease with unstable angina patients with platelet membrane protein CD63, PAC-1expression levels were significantly increased compared with healthy people, platelet membrane glycoprotein CD42b expression significantly reduced compared with healthy people, the difference was statistically significant (P<0.01);2. Coronary heart disease with unstable angina blood stasis syndrome platelet membrane protein CD63, PAC-1expression levels were significantly increased compared with healthy people, the platelet membrane glycoprotein CD42b expression levels of healthy people was significantly reduced, and the difference was statistically significant (P<0.01); patients with non-blood stasis, blood stasis syndrome platelet membrane glycoprotein CD63, PAC-1expression levels increase more obvious, platelet membrane glycoprotein CD42b downregulated degree than non-blood stasis group patients, the difference was statistically significant (P<0.05).3. Tanshinone Ⅱ A sulfonate injection in the treatment of coronary heart disease with unstable angina blood stasis in patients with angina pectoris:control group,8cases (19.51%), effective in22cases (53.66%),10cases (24.39%), increased1(2.44%). Treatment group,10cases (21.95%), effective in28cases (68.29%),4cases (9.76%), heavier0(0%). Control group, the total effective rate was73.17%total efficiency of the treatment group compared to90.24%, the difference between the two groups was statistically significant (P<0.05).4. Tanshinone II A sulfonate injection in the treatment of coronary heart disease with unstable angina patients with blood stasis blood stasis effect:control group,11cases (26.83%), effective in20cases (48.78%),10cases (24.39%) heavier0(0%). Treatment group,15cases (36.58%), effective in23cases (56.10%), and3cases (7.32%), heavier0(0%). Control group, the total effective rate was75.61%total efficiency of the treatment group compared to92.68%, the difference between the two groups was statistically significant (P<0.05).5. Tanshinone Ⅱ A sulfonate injection of coronary heart disease with unstable angina platelet function in patients with blood stasis:the control group and the treatment group after treatment compared with before treatment platelet membrane protein CD63, PAC-1expression level was significantly reduced, with significant difference (P<0.05); CD42b expression levels were significantly increased, with a statistically significant difference (P <0.05). The same time, the treatment group after treatment CD63, the reduction in the degree of the PAC-1expression than the control group is more obvious, with a statistically significant difference (P<0.01) and the CD42b upregulation degree than the control group obvious with statistics learning differences (P<0.05).Conclusion:1. Unstable angina patients with platelet membrane surface glycoprotein protein CD63, PAC-1expression levels increase CD42b expression levels down, is closely related to that platelet activation and the occurrence of unstable angina.2. Unstable angina blood stasis syndrome platelet membrane surface glycoprotein protein CD63, PAC-1expression levels increase CD42b expression levels down, change than non-blood stasis syndrome is more obvious, indicating that blood stasis and platelet activation are closely related.3. Tanshinone Ⅱ A Sulfonate Injection has a role in improving coronary heart disease angina symptoms in patients with unstable angina blood stasis, that they are one of the effective drugs for the treatment of coronary artery disease with unstable angina.4. Tanshinone Ⅱ A Sulfonate Injection to improve coronary heart disease unstable angina patients with blood stasis TCM syndrome, which is one of the effective drugs for the treatment of coronary artery disease with unstable angina blood stasis.5. Tanshinone Ⅱ A Sulfonate Injection can cut coronary heart disease unstable angina patients with blood stasis platelet membrane surface glycoprotein protein CD63, PAC-1expression, increase the expression of CD42b, inhibiting platelet activation, thereby inhibiting platelet adhesion, aggregation, release function, to the treatment of coronary heart disease with unstable angina and blood stasis. |
PDF Full Text Request